BioPharmSignal logoBioPharmSignal

Biotech News

Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial

Artivion (AORT)ArtivionClinical readout

ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent

Related news

DCTHDelcath Systems2026-07-09 12:00 EST

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AEMDAethlon Medical2026-07-13 12:01 EST

Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®

SGHTSight Sciences2026-08-19 11:05 EST

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

ANGOAngioDynamics2026-06-17 12:30 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

AEMDAethlon Medical2026-08-05 12:01 EST

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026

View all latest news

Artivion

Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...

Recent company news

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

AORTArtivion2026-07-28 20:10 EST

Artivion to Participate in Upcoming Investor Conferences

AORTArtivion2026-07-23 20:10 EST

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

AORTArtivion2026-06-29 11:00 EST

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

AORTArtivion2026-06-10 20:10 EST

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Stock data

Close
28.08 USD
Market cap
991.26M USD
Exchange
NYSE
Sector
MedTech
Location
United States